Tracon Pharmaceuticals
Tracon was a San Diego biotech whose endoglin antibody carotuximab failed a phase 3 trial in angiosarcoma and whose subcutaneous PD-L1 antibody envafolimab missed in sarcoma; it wound down in 2024.
Overview
Tracon Pharmaceuticals, based in San Diego, developed carotuximab (TRC105), an antibody against endoglin on tumour blood vessels, which failed the phase 3 TAPPAS trial with pazopanib in angiosarcoma in 2019, and then in-licensed the subcutaneous PD-L1 antibody envafolimab, whose ENVASARC trial in undifferentiated pleomorphic sarcoma did not meet its endpoint in 2023. The company ceased operations in 2024. Its trials remain on ClinicalTrials.gov under Tracon as lead sponsor.
Scorecard
All companies- approved products +6
- targets +2
- modalities +2
- regions +1
- registry trials +19
Similar pages
not linked directly; found by shared links- CompanyPTC Therapeutics
Shares Pivotal (registrational) trial, Clinical trial, Sarcomas (soft tissue, bone, GIST) and the tag ctgov-sponsor.
- CompanyCSL Limited
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyD3 Bio (Wuxi)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyDong-A ST
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEndo (now Keenova Therapeutics and Par Health)
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyEurofarma
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyGrifols
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.
- CompanyInsys Therapeutics
Shares Pivotal (registrational) trial, Clinical trial and the tag ctgov-sponsor.